Comparative Pharmacology
Head-to-head clinical analysis: METRA versus METRO I V.
Peer-Reviewed Evidence
Head-to-head clinical analysis: METRA versus METRO I V.
METRA vs METRO I.V.
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Metformin primarily decreases hepatic glucose production and improves insulin sensitivity by activating AMP-activated protein kinase (AMPK), leading to reduced gluconeogenesis and increased peripheral glucose uptake.
Metronidazole is a nitroimidazole antibiotic that exerts its bactericidal effect by entering bacterial cells and undergoing reduction by bacterial nitroreductases to form reactive intermediates that damage DNA, leading to cell death. It is selectively toxic to anaerobic bacteria and protozoa.
Adults: 20 mg orally once daily.
15-30 mg/kg IV loading dose, then 7.5-15 mg/kg IV every 6 hours. Typical adult dose: 500 mg IV every 6-8 hours.
None Documented
None Documented
Clinical Note
moderatePhenmetrazine + Atomoxetine
"Phenmetrazine may increase the hypertensive activities of Atomoxetine."
Clinical Note
moderatePhenmetrazine + Iobenguane
"The therapeutic efficacy of Iobenguane can be decreased when used in combination with Phenmetrazine."
Clinical Note
moderatePhenmetrazine + Acebutolol
"The risk or severity of adverse effects can be increased when Phenmetrazine is combined with Acebutolol."
Clinical Note
moderatePhenmetrazine + Isoxsuprine
Terminal elimination half-life: 3-7 hours (mean 4.5 hours). Increased to 8-15 hours in moderate-to-severe renal impairment (CrCl <30 mL/min).
8 hours (range 6-10 hours) in adults; prolonged to 12-24 hours in hepatic impairment.
Primarily renal: 70-80% unchanged drug via glomerular filtration and active tubular secretion; 15-20% biliary/fecal as metabolites.
Renal: 60-80% unchanged; fecal: 6-15% (includes metabolites); biliary: minor contribution.
Category C
Category C
Antibiotic (Nitroimidazole)
Antibiotic (Nitroimidazole)
"The risk or severity of adverse effects can be increased when Phenmetrazine is combined with Isoxsuprine."